Phase 1 × Completed × Triple Negative Breast Neoplasms × Clear all A Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following Chemotherapy
Phase 1 Completed
31 enrolled 12 charts
Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC)
Phase 1 Completed
16 enrolled 10 charts
RadioPARP
Phase 1 Completed
24 enrolled
A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Tumors
Phase 1 Completed
48 enrolled
The Role of Bexarotene in Inducing Susceptibility to Chemotherapy in Metastatic TNBC
Phase 1 Completed
12 enrolled
Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors
Phase 1 Completed
60 enrolled
Safety of TT-00420 (Tinengotinib) Monotherapy in Patients With Advanced Solid Tumors and Triple Negative Breast Cancer
Phase 1 Completed
48 enrolled
INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors
Phase 1 Completed
54 enrolled
A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Phase 1 Completed
272 enrolled
A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands
Phase 1 Completed
185 enrolled
Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery
Phase 1 Completed
73 enrolled
Study of XB002 in Subjects With Solid Tumors (JEWEL-101)
Phase 1 Completed
269 enrolled
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
Phase 1 Completed
121 enrolled
Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer
Phase 1 Completed
29 enrolled
First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours
Phase 1 Completed
60 enrolled
Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer
Phase 1 Completed
18 enrolled
PhI to Solid Tumors and PhII to Locally Advanced or mTNBC
Phase 1 Completed
21 enrolled
A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers
Phase 1 Completed
129 enrolled 32 charts
DUET-3
Phase 1 Completed
198 enrolled
A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies
Phase 1 Completed
35 enrolled
Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases
Phase 1 Completed
36 enrolled 16 charts
A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer
Phase 1 Completed
52 enrolled 21 charts
Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer
Phase 1 Completed
44 enrolled
Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer
Phase 1 Completed
34 enrolled
Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast Cancer
Phase 1 Completed
12 enrolled
CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
Phase 1 Completed
117 enrolled
Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer
Phase 1 Completed
9 enrolled 17 charts
Study of AMG 650 in Adult Participants With Advanced Solid Tumors
Phase 1 Completed
66 enrolled
Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours
Phase 1 Completed
92 enrolled
TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers
Phase 1 Completed
38 enrolled
cMet CAR RNA T Cells Targeting Breast Cancer
Phase 1 Completed
6 enrolled
TNBC
Phase 1 Completed
10 enrolled
Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer
Phase 1 Completed
28 enrolled 21 charts
DUET-4
Phase 1 Completed
78 enrolled
A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors
Phase 1 Completed
69 enrolled
A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer
Phase 1 Completed
83 enrolled
A Safety Study of SGN-LIV1A in Breast Cancer Patients
Phase 1 Completed
290 enrolled
Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer or Metastatic Breast Cancer
Phase 1 Completed
12 enrolled
A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat
Phase 1 Completed
298 enrolled
DUET-2
Phase 1 Completed
150 enrolled
Phase 1b Trial of Dinaciclib With Pembrolizumab for Advanced Breast Cancer
Phase 1 Completed
32 enrolled
A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)
Phase 1 Completed
110 enrolled 80 charts
A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC
Phase 1 Completed
32 enrolled
Study of the Glutaminase Inhibitor CB-839 in Solid Tumors
Phase 1 Completed
210 enrolled
Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer
Phase 1 Completed
27 enrolled 16 charts
A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients
Phase 1 Completed
98 enrolled
ARCS-Multi
Phase 1 Completed
173 enrolled
Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells
Phase 1 Completed
5 enrolled
A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors
Phase 1 Completed
139 enrolled
A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors
Phase 1 Completed
182 enrolled